中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 4
Apr.  2021
Turn off MathJax
Article Contents

Advances in the pathogenesis and treatment of acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2021.04.005
  • Received Date: 2021-01-07
  • Accepted Date: 2021-03-02
  • Published Date: 2021-04-20
  • Acute-on-chronic liver failure (ACLF) is a type of severe clinical syndrome which occurs on the basis of chronic liver diseases and has the main clinical features of acute liver decompensation, extrahepatic organ damage, and high short-term mortality rate. The underlying diseases of chronic liver diseases are mainly alcoholic hepatitis and chronic hepatitis C in Western countries, while chronic hepatitis B is the main underlying disease of chronic liver diseases in China and the Asia-Pacific region. Although there are differences in underlying liver diseases between the East and the West, the common pathological basis of most ACLF patients is usually liver fibrosis or cirrhosis caused by long-term chronic liver injury. At present, the research on ACLF has been widely carried out all over the world; however, due to the differences in region, population, and disease triggers, no consensus has been reached on the definition, diagnostic criteria, and disease management of ACLF between the East and the West. This article elaborates on the definition, pathogenesis, and management of ACLF, in order to provide clinicians with new therapeutic strategies that would improve the prognosis of ACLF.

     

  • loading
  • [1]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure[J]. Inter J Epidemiol Infect Dis, 2006, 33(4): 217-221. DOI: 10.3760/cma.j.issn.1673-4149.2006.04.001.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南[J]. 国际流行病学传染病学杂志, 2006, 33(4): 217-221. DOI: 10.3760/cma.j.issn.1673-4149.2006.04.001.
    [2]
    MOREAU R, JALAN R, GINES P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology, 2013, 144(7): 1426-1437. DOI: 10.1053/j.gastro.2013.02.042.
    [3]
    BAJAJ JS, O'LEARY JG, REDDY KR, et al. Survival in infection -related acute-on-chronic liver failure is defined by extrahepatic organ failures[J]. Hepatology, 2014, 60(1): 250-256. DOI: 10.1002/hep.27077.
    [4]
    WU T, LI J, SHAO L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67(12): 2181-2191. DOI: 10.1136/gutjnl-2017-314641.
    [5]
    JALAN R, STADLBAUER V, SEN S, et al. Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: A prospective cohort study[J]. Crit Care, 2012, 16(6): R227. DOI: 10.1186/cc11882.
    [6]
    SHI Y, YANG Y, HU Y, et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults[J]. Hepatology, 2015, 62(1): 232-242. DOI: 10.1002/hep.27795.
    [7]
    HERNAEZ R, SOLÀ E, MOREAU R, et al. Acute-on-chronic liver failure: An update[J]. Gut, 2017, 66(3): 541-553. DOI: 10.1136/gutjnl-2016-312670.
    [8]
    CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
    [9]
    GARG V, GARG H, KHAN A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure[J]. Gastroenterology, 2012, 142(3): 505-512.e1. DOI: 10.1053/j.gastro.2011.11.027.
    [10]
    CLÀRIA J, ARROYO V, MOREAU R. The acute-on-chronic liver failure syndrome, or when the innate immune system goes astray[J]. J Immunol, 2016, 197(10): 3755-3761. DOI: 10.4049/jimmunol.1600818.
    [11]
    ARROYO V, MOREAU R, JALAN R. Acute-on-chronic liver failure [J]. N Engl J Med, 2020, 382(22): 2137-2145. DOI: 10.1056/NEJMra1914900.
    [12]
    SARIN SK, KUMAR A, ALMEIDA JA, et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) [J]. Hepatol Int, 2019, 3(1): 269-282. DOI: 10.1007/s12072-008-9106-x.
    [13]
    WANG J, MA K, HAN M, et al. Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: Validation of the TPPM model[J]. Hepatol Int, 2014, 8(1): 64-71. DOI: 10.1007/s12072-013-9485-5.
    [14]
    FERNÁNDEZ J, ACEVEDO J, WIEST R, et al. Bacterial and fungal infections in acute-on-chronic liver failure: Prevalence, characteristics and impact on prognosis[J]. Gut, 2018, 67(10): 1870-1880. DOI: 10.1136/gutjnl-2017-314240.
    [15]
    THURSZ MR, RICHARDSON P, ALLISON M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis[J]. N Engl J Med, 2015, 372(17): 1619-1628. DOI: 10.1056/NEJMoa1412278.
    [16]
    SERSTÉ T, CORNILLIE A, NJIMI H, et al. The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis[J]. J Hepatol, 2018, 69(2): 318-324. DOI: 10.1016/j.jhep.2018.02.022.
    [17]
    HASSANEIN TI, TOFTENG F, BROWN RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis[J]. Hepatology, 2007, 46(6): 1853-1862. DOI: 10.1002/hep.21930.
    [18]
    KRIBBEN A, GERKEN G, HAAG S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure[J]. Gastroenterology, 2012, 142(4): 782-789.e3. DOI: 10.1053/j.gastro.2011.12.056.
    [19]
    BAÑARES R, NEVENS F, LARSEN FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial[J]. Hepatology, 2013, 57(3): 1153-1162. DOI: 10.1002/hep.26185.
    [20]
    YAO J, LI S, ZHOU L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure[J]. J Clin Apher, 2019, 34(4): 392-398. DOI: 10.1002/jca.21690.
    [21]
    SHEN Y, WANG XL, WANG B, et al. Survival benefits with artificial liver support system for acute-on-chronic liver failure: A time series-based meta-analysis[J]. Medicine (Baltimore), 2016, 95(3): e2506. DOI: 10.1097/MD.0000000000002506.
    [22]
    PIANO S, SCHMIDT HH, ARIZA X, et al. Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome[J]. Clin Gastroenterol Hepatol, 2018, 16(11): 1792-1800.e3. DOI: 10.1016/j.cgh.2018.01.035.
    [23]
    THULUVATH PJ, THULUVATH AJ, HANISH S, et al. Liver transplantation in patients with multiple organ failures: Feasibility and outcomes[J]. J Hepatol, 2018, 69(5): 1047-1056. DOI: 10.1016/j.jhep.2018.07.007.
    [24]
    SUNDARAM V, JALAN R, WU T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation[J]. Gastroenterology, 2019, 156(5): 1381-1391.e3. DOI: 10.1053/j.gastro.2018.12.007.
    [25]
    LIN BL, CHEN JF, QIU WH, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial[J]. Hepatology, 2017, 66(1): 209-219. DOI: 10.1002/hep.29189.
    [26]
    SAHA BK, MAHTAB MA, AKBAR S, et al. Therapeutic implications of granulocyte colony stimulating factor in patients with acute- on-chronic liver failure: Increased survival and containment of liver damage[J]. Hepatol Int, 2017, 11(6): 540-546. DOI: 10.1007/s12072-017-9814-1.
    [27]
    XIANG X, FENG D, HWANG S, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice[J]. J Hepatol, 2020, 72(4): 736-745. DOI: 10.1016/j.jhep.2019.11.013.
    [28]
    XIANG X, HWANG S, FENG D, et al. Interleukin-22 in alcoholic hepatitis and beyond[J]. Hepatol Int, 2020, 14(5): 667-676. DOI: 10.1007/s12072-020-10082-6.
    [29]
    ARAB JP, SEHRAWAT TS, SIMONETTO DA, et al. An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis[J]. Hepatology, 2020, 72(2): 441-453. DOI: 10.1002/hep.31046.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Article Metrics

    Article views (1318) PDF downloads(222) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return